inclusion criteria: 1. age \>18 2. sars cov-2 laboratory positive test, obtained within 14 days of enrollment 3. hospitalized 4. covid-19 symptomatic (cough, fevers, shortness of breath, and/or sputum production) 5. has a room air pulse oximetry of ≤94% and requires supplemental oxygen therapy 6. patients of childbearing potential who agree to use acceptable methods of contraception for 90 days after last administration of study investigational product (ip) 7. patients who are receiving standard of care therapies for covid-19 that are not fda approved are eligible for this study 8. subjects must be able to consent to the study (i.e., glasgow coma scale score of ≥14) 9. patients are required to have controlled blood pressure of \<160/96 and a pulse of \<110.

inclusion criteria: 1. age \>18 2. sars cov-2 laboratory positive test, obtained within 14 days of enrollment 3. hospitalized 4. covid-19 symptomatic (cough, fevers, shortness of breath, and/or sputum production) 5. has a room air pulse oximetry of ≤94% and requires supplemental oxygen therapy 6. patients of childbearing potential who agree to use acceptable methods of contraception for 90 days after last administration of study investigational product (ip) 7. patients who are receiving standard of care therapies for covid-19 that are not fda approved are eligible for this study 8. subjects must be able to consent to the study (i.e., glasgow coma scale score of ≥14) 9. patients are required to have controlled blood pressure of \<160/96 and a pulse of \<110.

inclusion criteria: age >18 sars cov-2 laboratory positive test, obtained within 14 days of enrollment hospitalized covid-19 symptomatic (cough, fevers, shortness of breath, and/or sputum production) has a room air pulse oximetry of ≤94% and requires supplemental oxygen therapy patients of childbearing potential who agree to use acceptable methods of contraception for 90 days after last administration of study investigational product (ip) patients who are receiving standard of care therapies for covid-19 that are not fda approved are eligible for this study subjects must be able to consent to the study (i.e., glasgow coma scale score of ≥14) patients are required to have controlled blood pressure of <160/96 and a pulse of <110.

inclusion criteria: age >18 sars cov-2 laboratory positive test, obtained within 14 days of enrollment hospitalized covid-19 symptomatic (cough, fevers, shortness of breath, and/or sputum production) has a room air pulse oximetry of ≤94% and requires supplemental oxygen therapy patients of childbearing potential who agree to use acceptable methods of contraception for 90 days after last administration of study investigational product (ip) patients who are receiving standard of care therapies for covid-19 that are not fda approved are eligible for this study subjects must be able to consent to the study (i.e., glasgow coma scale score of ≥14) patients are required to have controlled blood pressure of <160/96 and a pulse of <110.

inclusion criteria: age >18 sars cov-2 laboratory positive test, obtained within 14 days of enrollment hospitalized covid-19 symptomatic (cough, fevers, shortness of breath, and/or sputum production) has a room air pulse oximetry of ≤94% and requires supplemental oxygen therapy patients of childbearing potential who agree to use acceptable methods of contraception for 90 days after last administration of study ip patients who are receiving standard of care therapies for covid-19 that are not fda approved are eligible for this study subjects must be able to consent to the study (i.e., glasgow coma scale score of ≥14) patients are required to have controlled blood pressure of <160/96 and a pulse of <110.

inclusion criteria: age >18 sars cov-2 laboratory positive test, obtained within 14 days of enrollment hospitalized covid-19 symptomatic (cough, fevers, shortness of breath, and/or sputum production) has a room air pulse oximetry of ≤94% and requires supplemental oxygen therapy patients of childbearing potential who agree to use acceptable methods of contraception for 90 days after last administration of study ip patients who are receiving standard of care therapies for covid-19 that are not fda approved are eligible for this study subjects must be able to consent to the study (i.e., glasgow coma scale score of ≥14) patients are required to have controlled blood pressure of <160/96 and a pulse of <110.

inclusion criteria: 1. age >18 2. sars cov-2 laboratory positive test, obtained within 14 days of enrollment 3. hospitalized 4. covid-19 symptomatic (cough, fevers, shortness of breath, and/or sputum production) 5. has a room air pulse oximetry of ≤94% and requires supplemental oxygen therapy 6. patients of childbearing potential who agree to use acceptable methods of contraception for 90 days after last administration of study ip 7. patients who are receiving standard of care therapies for covid-19 that are not fda approved are eligible for this study 8. subjects must be able to consent to the study (i.e., glasgow coma scale score of ≥14) 9. patients are required to have controlled blood pressure of <160/96 and a pulse of <110.

inclusion criteria: 1. age >18 2. sars cov-2 laboratory positive test, obtained within 14 days of enrollment 3. hospitalized 4. covid-19 symptomatic (cough, fevers, shortness of breath, and/or sputum production) 5. has a room air pulse oximetry of ≤94% and requires supplemental oxygen therapy 6. patients of childbearing potential who agree to use acceptable methods of contraception for 90 days after last administration of study ip 7. patients who are receiving standard of care therapies for covid-19 that are not fda approved are eligible for this study 8. subjects must be able to consent to the study (i.e., glasgow coma scale score of ≥14) 9. patients are required to have controlled blood pressure of <160/96 and a pulse of <110.